SrasV1, PascalFrancis, Corpus, bibRecord, 000345

Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents

Identifieur interne : 000345 ( PascalFrancis/Corpus ); précédent : 000344; suivant : 000346

Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents

Auteurs : Masahiro Ikejiri ; Masayuki Saijo ; Shigeru Morikawa ; Shuetsu Fukushi ; Tetsuya Mizutani ; Ichiro Kurane ; Tokumi Maruyama

Source :

Bioorganic & medicinal chemistry letters : (Print) [ 0960-894X ] ; 2007.

RBID : Pascal:07-0465126

Descripteurs français

Pascal (Inist)
- Synthèse chimique, Relation structure activité, Analogue nucléoside, Antiviral, Virus syndrome respiratoire aigu sévère, Purine nucléoside, In vitro, Purine(9-[3-benzoyloxy-2-(hydroxyméthyl)cyclobutyl]-6-chloro), Cyclobutane-1,2-diméthanol dérivé, 1,2,4-Triazole dérivé.

English descriptors

KwdEn :
- Antiviral, Chemical synthesis, In vitro, Nucleoside analog, Purine nucleoside, Severe acute respiratory syndrome virus, Structure activity relation.

Abstract

Nucleoside analogues that have 6-chloropurine as the nucleobase were synthesized and evaluated for anti-SARS-CoV activity by plaque reduction and yield reduction assays in order to develop novel anti-SARS-CoV agents. Among these analogues, two compounds, namely, 1 and 11, exhibited promising anti-SARS-CoV activity that was comparable to those of mizoribine and ribavirin, which are known anti-SARS-CoV agents. Moreover, we observed several SAR trends such as the antiviral effects of the 6-chloropurine moiety, unprotected 5'-hydroxyl group and benzoylated 5'-hydroxyl group.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0960-894X`
A03		`1`		`@0 Bioorg. med. chem. lett. : (Print)`
A05				`@2 17`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents`
A11	`01`	`1`		`@1 IKEJIRI (Masahiro)`
A11	`02`	`1`		`@1 SAIJO (Masayuki)`
A11	`03`	`1`		`@1 MORIKAWA (Shigeru)`
A11	`04`	`1`		`@1 FUKUSHI (Shuetsu)`
A11	`05`	`1`		`@1 MIZUTANI (Tetsuya)`
A11	`06`	`1`		`@1 KURANE (Ichiro)`
A11	`07`	`1`		`@1 MARUYAMA (Tokumi)`
A14	`01`			`@1 Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido @2 Sanuki, Kagawa 769-2193 @3 JPN @Z 1 aut. @Z 7 aut.`
A14	`02`			`@1 Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen @2 Musashimurayama, Tokyo 208-0011 @3 JPN @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A20				`@1 2470-2473`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 22446 @5 354000143538260160`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A47	`01`	`1`		`@0 07-0465126`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Bioorganic & medicinal chemistry letters : (Print)`
A66	`01`			`@0 GBR`
A99				`@0 1/2 p. ref. et notes`
C01	`01`		`ENG`	@0 Nucleoside analogues that have 6-chloropurine as the nucleobase were synthesized and evaluated for anti-SARS-CoV activity by plaque reduction and yield reduction assays in order to develop novel anti-SARS-CoV agents. Among these analogues, two compounds, namely, 1 and 11, exhibited promising anti-SARS-CoV activity that was comparable to those of mizoribine and ribavirin, which are known anti-SARS-CoV agents. Moreover, we observed several SAR trends such as the antiviral effects of the 6-chloropurine moiety, unprotected 5'-hydroxyl group and benzoylated 5'-hydroxyl group.
C02	`01`	`X`		`@0 002B02S05`
C03	`01`	`X`	`FRE`	`@0 Synthèse chimique @5 01`
C03	`01`	`X`	`ENG`	`@0 Chemical synthesis @5 01`
C03	`01`	`X`	`SPA`	`@0 Síntesis química @5 01`
C03	`02`	`X`	`FRE`	`@0 Relation structure activité @5 02`
C03	`02`	`X`	`ENG`	`@0 Structure activity relation @5 02`
C03	`02`	`X`	`SPA`	`@0 Relación estructura actividad @5 02`
C03	`03`	`X`	`FRE`	`@0 Analogue nucléoside @5 03`
C03	`03`	`X`	`ENG`	`@0 Nucleoside analog @5 03`
C03	`03`	`X`	`SPA`	`@0 Análogo nucleósido @5 03`
C03	`04`	`X`	`FRE`	`@0 Antiviral @5 04`
C03	`04`	`X`	`ENG`	`@0 Antiviral @5 04`
C03	`04`	`X`	`SPA`	`@0 Antiviral @5 04`
C03	`05`	`X`	`FRE`	`@0 Virus syndrome respiratoire aigu sévère @2 NW @5 05`
C03	`05`	`X`	`ENG`	`@0 Severe acute respiratory syndrome virus @2 NW @5 05`
C03	`05`	`X`	`SPA`	`@0 Severe acute respiratory syndrome virus @2 NW @5 05`
C03	`06`	`X`	`FRE`	`@0 Purine nucléoside @5 06`
C03	`06`	`X`	`ENG`	`@0 Purine nucleoside @5 06`
C03	`06`	`X`	`SPA`	`@0 Purina nucleósido @5 06`
C03	`07`	`X`	`FRE`	`@0 In vitro @5 08`
C03	`07`	`X`	`ENG`	`@0 In vitro @5 08`
C03	`07`	`X`	`SPA`	`@0 In vitro @5 08`
C03	`08`	`X`	`FRE`	`@0 Purine(9-[3-benzoyloxy-2-(hydroxyméthyl)cyclobutyl]-6-chloro) @2 NK @2 FR @4 INC @5 76`
C03	`09`	`X`	`FRE`	`@0 Cyclobutane-1,2-diméthanol dérivé @2 NK @4 INC @5 77`
C03	`10`	`X`	`FRE`	`@0 1,2,4-Triazole dérivé @4 INC @5 91`
C07	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW`
C07	`02`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`04`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`04`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`05`	`3`	`FRE`	`@0 Chlore composé organique @5 07`
C07	`05`	`3`	`ENG`	`@0 Organic chlorine compounds @5 07`
N21				`@1 302`

Format Inist (serveur)

NO :	PASCAL 07-0465126 INIST
ET :	Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents
AU :	IKEJIRI (Masahiro); SAIJO (Masayuki); MORIKAWA (Shigeru); FUKUSHI (Shuetsu); MIZUTANI (Tetsuya); KURANE (Ichiro); MARUYAMA (Tokumi)
AF :	Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido/Sanuki, Kagawa 769-2193/Japon (1 aut., 7 aut.); Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen/Musashimurayama, Tokyo 208-0011/Japon (2 aut., 3 aut., 4 aut., 5 aut., 6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Bioorganic & medicinal chemistry letters : (Print); ISSN 0960-894X; Royaume-Uni; Da. 2007; Vol. 17; No. 9; Pp. 2470-2473
LA :	Anglais
EA :	Nucleoside analogues that have 6-chloropurine as the nucleobase were synthesized and evaluated for anti-SARS-CoV activity by plaque reduction and yield reduction assays in order to develop novel anti-SARS-CoV agents. Among these analogues, two compounds, namely, 1 and 11, exhibited promising anti-SARS-CoV activity that was comparable to those of mizoribine and ribavirin, which are known anti-SARS-CoV agents. Moreover, we observed several SAR trends such as the antiviral effects of the 6-chloropurine moiety, unprotected 5'-hydroxyl group and benzoylated 5'-hydroxyl group.
CC :	002B02S05
FD :	Synthèse chimique; Relation structure activité; Analogue nucléoside; Antiviral; Virus syndrome respiratoire aigu sévère; Purine nucléoside; In vitro; Purine(9-[3-benzoyloxy-2-(hydroxyméthyl)cyclobutyl]-6- chloro); Cyclobutane-1,2-diméthanol dérivé; 1,2,4-Triazole dérivé
FG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Chlore composé organique
ED :	Chemical synthesis; Structure activity relation; Nucleoside analog; Antiviral; Severe acute respiratory syndrome virus; Purine nucleoside; In vitro
EG :	Coronavirus; Coronaviridae; Nidovirales; Virus; Organic chlorine compounds
SD :	Síntesis química; Relación estructura actividad; Análogo nucleósido; Antiviral; Severe acute respiratory syndrome virus; Purina nucleósido; In vitro
LO :	INIST-22446.354000143538260160
ID :	07-0465126

Links to Exploration step

Pascal:07-0465126

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents</title>
<author><name sortKey="Ikejiri, Masahiro" sort="Ikejiri, Masahiro" uniqKey="Ikejiri M" first="Masahiro" last="Ikejiri">Masahiro Ikejiri</name>
<affiliation><inist:fA14 i1="01"><s1>Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido</s1>
<s2>Sanuki, Kagawa 769-2193</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name>
<affiliation><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morikawa, Shigeru" sort="Morikawa, Shigeru" uniqKey="Morikawa S" first="Shigeru" last="Morikawa">Shigeru Morikawa</name>
<affiliation><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name>
<affiliation><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mizutani, Tetsuya" sort="Mizutani, Tetsuya" uniqKey="Mizutani T" first="Tetsuya" last="Mizutani">Tetsuya Mizutani</name>
<affiliation><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kurane, Ichiro" sort="Kurane, Ichiro" uniqKey="Kurane I" first="Ichiro" last="Kurane">Ichiro Kurane</name>
<affiliation><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maruyama, Tokumi" sort="Maruyama, Tokumi" uniqKey="Maruyama T" first="Tokumi" last="Maruyama">Tokumi Maruyama</name>
<affiliation><inist:fA14 i1="01"><s1>Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido</s1>
<s2>Sanuki, Kagawa 769-2193</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0465126</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0465126 INIST</idno>
<idno type="RBID">Pascal:07-0465126</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000345</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents</title>
<author><name sortKey="Ikejiri, Masahiro" sort="Ikejiri, Masahiro" uniqKey="Ikejiri M" first="Masahiro" last="Ikejiri">Masahiro Ikejiri</name>
<affiliation><inist:fA14 i1="01"><s1>Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido</s1>
<s2>Sanuki, Kagawa 769-2193</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Saijo, Masayuki" sort="Saijo, Masayuki" uniqKey="Saijo M" first="Masayuki" last="Saijo">Masayuki Saijo</name>
<affiliation><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Morikawa, Shigeru" sort="Morikawa, Shigeru" uniqKey="Morikawa S" first="Shigeru" last="Morikawa">Shigeru Morikawa</name>
<affiliation><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fukushi, Shuetsu" sort="Fukushi, Shuetsu" uniqKey="Fukushi S" first="Shuetsu" last="Fukushi">Shuetsu Fukushi</name>
<affiliation><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mizutani, Tetsuya" sort="Mizutani, Tetsuya" uniqKey="Mizutani T" first="Tetsuya" last="Mizutani">Tetsuya Mizutani</name>
<affiliation><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kurane, Ichiro" sort="Kurane, Ichiro" uniqKey="Kurane I" first="Ichiro" last="Kurane">Ichiro Kurane</name>
<affiliation><inist:fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Maruyama, Tokumi" sort="Maruyama, Tokumi" uniqKey="Maruyama T" first="Tokumi" last="Maruyama">Tokumi Maruyama</name>
<affiliation><inist:fA14 i1="01"><s1>Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido</s1>
<s2>Sanuki, Kagawa 769-2193</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Bioorganic & medicinal chemistry letters : (Print)</title>
<title level="j" type="abbreviated">Bioorg. med. chem. lett. : (Print)</title>
<idno type="ISSN">0960-894X</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Bioorganic & medicinal chemistry letters : (Print)</title>
<title level="j" type="abbreviated">Bioorg. med. chem. lett. : (Print)</title>
<idno type="ISSN">0960-894X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Chemical synthesis</term>
<term>In vitro</term>
<term>Nucleoside analog</term>
<term>Purine nucleoside</term>
<term>Severe acute respiratory syndrome virus</term>
<term>Structure activity relation</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Synthèse chimique</term>
<term>Relation structure activité</term>
<term>Analogue nucléoside</term>
<term>Antiviral</term>
<term>Virus syndrome respiratoire aigu sévère</term>
<term>Purine nucléoside</term>
<term>In vitro</term>
<term>Purine(9-[3-benzoyloxy-2-(hydroxyméthyl)cyclobutyl]-6-chloro)</term>
<term>Cyclobutane-1,2-diméthanol dérivé</term>
<term>1,2,4-Triazole dérivé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Nucleoside analogues that have 6-chloropurine as the nucleobase were synthesized and evaluated for anti-SARS-CoV activity by plaque reduction and yield reduction assays in order to develop novel anti-SARS-CoV agents. Among these analogues, two compounds, namely, 1 and 11, exhibited promising anti-SARS-CoV activity that was comparable to those of mizoribine and ribavirin, which are known anti-SARS-CoV agents. Moreover, we observed several SAR trends such as the antiviral effects of the 6-chloropurine moiety, unprotected 5'-hydroxyl group and benzoylated 5'-hydroxyl group.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0960-894X</s0>
</fA01>
<fA03 i2="1"><s0>Bioorg. med. chem. lett. : (Print)</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>IKEJIRI (Masahiro)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SAIJO (Masayuki)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MORIKAWA (Shigeru)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>FUKUSHI (Shuetsu)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>MIZUTANI (Tetsuya)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>KURANE (Ichiro)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MARUYAMA (Tokumi)</s1>
</fA11>
<fA14 i1="01"><s1>Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido</s1>
<s2>Sanuki, Kagawa 769-2193</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen</s1>
<s2>Musashimurayama, Tokyo 208-0011</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>2470-2473</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>22446</s2>
<s5>354000143538260160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA47 i1="01" i2="1"><s0>07-0465126</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Bioorganic & medicinal chemistry letters : (Print)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fA99><s0>1/2 p. ref. et notes</s0>
</fA99>
<fC01 i1="01" l="ENG"><s0>Nucleoside analogues that have 6-chloropurine as the nucleobase were synthesized and evaluated for anti-SARS-CoV activity by plaque reduction and yield reduction assays in order to develop novel anti-SARS-CoV agents. Among these analogues, two compounds, namely, 1 and 11, exhibited promising anti-SARS-CoV activity that was comparable to those of mizoribine and ribavirin, which are known anti-SARS-CoV agents. Moreover, we observed several SAR trends such as the antiviral effects of the 6-chloropurine moiety, unprotected 5'-hydroxyl group and benzoylated 5'-hydroxyl group.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Synthèse chimique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Chemical synthesis</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Síntesis química</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Relation structure activité</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Structure activity relation</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Relación estructura actividad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Analogue nucléoside</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nucleoside analog</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Análogo nucleósido</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0>
<s2>NW</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0>
<s2>NW</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Purine nucléoside</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Purine nucleoside</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Purina nucleósido</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>In vitro</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>In vitro</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>In vitro</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Purine(9-[3-benzoyloxy-2-(hydroxyméthyl)cyclobutyl]-6-chloro)</s0>
<s2>NK</s2>
<s2>FR</s2>
<s4>INC</s4>
<s5>76</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Cyclobutane-1,2-diméthanol dérivé</s0>
<s2>NK</s2>
<s4>INC</s4>
<s5>77</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>1,2,4-Triazole dérivé</s0>
<s4>INC</s4>
<s5>91</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="3" l="FRE"><s0>Chlore composé organique</s0>
<s5>07</s5>
</fC07>
<fC07 i1="05" i2="3" l="ENG"><s0>Organic chlorine compounds</s0>
<s5>07</s5>
</fC07>
<fN21><s1>302</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 07-0465126 INIST</NO>
<ET>Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents</ET>
<AU>IKEJIRI (Masahiro); SAIJO (Masayuki); MORIKAWA (Shigeru); FUKUSHI (Shuetsu); MIZUTANI (Tetsuya); KURANE (Ichiro); MARUYAMA (Tokumi)</AU>
<AF>Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido/Sanuki, Kagawa 769-2193/Japon (1 aut., 7 aut.); Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen/Musashimurayama, Tokyo 208-0011/Japon (2 aut., 3 aut., 4 aut., 5 aut., 6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Bioorganic & medicinal chemistry letters : (Print); ISSN 0960-894X; Royaume-Uni; Da. 2007; Vol. 17; No. 9; Pp. 2470-2473</SO>
<LA>Anglais</LA>
<EA>Nucleoside analogues that have 6-chloropurine as the nucleobase were synthesized and evaluated for anti-SARS-CoV activity by plaque reduction and yield reduction assays in order to develop novel anti-SARS-CoV agents. Among these analogues, two compounds, namely, 1 and 11, exhibited promising anti-SARS-CoV activity that was comparable to those of mizoribine and ribavirin, which are known anti-SARS-CoV agents. Moreover, we observed several SAR trends such as the antiviral effects of the 6-chloropurine moiety, unprotected 5'-hydroxyl group and benzoylated 5'-hydroxyl group.</EA>
<CC>002B02S05</CC>
<FD>Synthèse chimique; Relation structure activité; Analogue nucléoside; Antiviral; Virus syndrome respiratoire aigu sévère; Purine nucléoside; In vitro; Purine(9-[3-benzoyloxy-2-(hydroxyméthyl)cyclobutyl]-6- chloro); Cyclobutane-1,2-diméthanol dérivé; 1,2,4-Triazole dérivé</FD>
<FG>Coronavirus; Coronaviridae; Nidovirales; Virus; Chlore composé organique</FG>
<ED>Chemical synthesis; Structure activity relation; Nucleoside analog; Antiviral; Severe acute respiratory syndrome virus; Purine nucleoside; In vitro</ED>
<EG>Coronavirus; Coronaviridae; Nidovirales; Virus; Organic chlorine compounds</EG>
<SD>Síntesis química; Relación estructura actividad; Análogo nucleósido; Antiviral; Severe acute respiratory syndrome virus; Purina nucleósido; In vitro</SD>
<LO>INIST-22446.354000143538260160</LO>
<ID>07-0465126</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000345 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000345 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:07-0465126
   |texte=   Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents

Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri